中国国际金融股份有限公司 使用部分暂时闲置募集资金进行现金管理及以通知存款、协定存 款等方式存放募集资金的核查意见 中国国际金融股份有限公司（以下简称"中金公司"或"保荐机构"）作为诺诚健 华医药有限公司（以下简称"诺诚健华"或"公司"）的保荐机构，根据《中华人民共 和国公司法》《中华人民共和国证券法》《上海证券交易所科创板股票上市规则》《上 市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》《上海证券交易 所科创板上市公司自律监管指引第 1 号——规范运作》等有关法律、行政法规、部门规 章及业务规则的要求，对诺诚健华使用部分暂时闲置募集资金进行现金管理及以通知存 款、协定存款等方式存放募集资金的事项进行了认真、审慎核查，具体情况如下： 一、募集资金基本情况 公司首次公开发行股票并在科创板上市的注册申请于 2022 年 7 月 15 日经中国证 券监督管理委员会同意（证监许可[2022]1524 号《关于同意诺诚健华医药有限公司首次 公开发行股票注册的批复》），公司据此公开发行了人民币普通股 264,648,217 股股票， 每股发行价格为人民币 11.03 元，募集资金总额为人民币 291, ...

| A 股代码：688428 | A 股简称：诺诚健华 | 公告编号：2024-010 | | --- | --- | --- | | 港股代码：09969 | 港股简称：诺诚健华 | | 诺诚健华医药有限公司 董事会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 董事会会议召开情况 1 董事会同意公司在确保不影响募集资金投资项目建设及募集资金使用安排， 并有效控制风险的前提下，将最高不超过 10 亿元人民币的暂时闲置募集资金进 行现金管理，购买安全性高、流动性好的低风险投资产品（包括但不限于结构性 存款、定期存款、大额存单等），在董事会审议通过之日起 12 个月内可进行该现 金管理，且该 10 亿元人民币额度可循环滚动使用；并同意公司以通知存款、协 定存款等方式存放募集资金，存款期限自公司董事会审议通过之日起不超过 12 个月。 表决结果：8 票赞成，0 票弃权，0 票反对。 具 体 内 容 详 见 公 司 于 2024 年 5 月 31 日 在 上 海 证 券 交 易 所 网 站 （www.sse.co ...

| | | 诺诚健华医药有限公司 关于向激励对象授予预留限制性股票的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 限制性股票预留授予日：2024 年 5 月 30 日 限制性股票预留授予数量：173.700 万股，约占目前公司已发行股份总数 176,258.2452 万股的 0.10% 股权激励方式：第二类限制性股票 诺诚健华医药有限公司（以下简称"诺诚健华"或"公司"）《2023 年科创板限制 性股票激励计划（草案）》（以下简称"《激励计划（草案）》"）规定的公司 2023 年科创板限制性股票激励计划（以下简称"本次激励计划"或"本激励计划"）的预留 授予条件已经成就，根据公司 2023 年股东周年大会的授权，公司于 2024 年 5 月 30 日召开董事会审议通过向激励对象授予预留限制性股票，确定公司本次激励计 划的预留授予日为 2024 年 5 月 30 日，以 6.95 元/股的授予价格向 47 名符合授予 条件的激励对象授予 173.700 万股限制性股票。现将有关事项说明如下： 本次实际 ...

关于使用部分暂时闲置募集资金进行现金管理及 以通知存款、协定存款等方式存放募集资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 诺诚健华医药有限公司 2024 年 5 月 30 日，诺诚健华医药有限公司（以下简称"公司"或"诺诚健 华"）召开董事会，审议通过了《使用部分暂时闲置募集资金进行现金管理及以 通知存款、协定存款等方式存放募集资金》的议案，同意公司在确保不影响募集 资金投资项目建设及募集资金使用安排，并有效控制风险的前提下，将最高不超 过 10 亿元人民币的暂时闲置募集资金进行现金管理，购买安全性高、流动性好 的低风险投资产品（包括但不限于结构性存款、定期存款、大额存单等），在董 事会审议通过之日起 12 个月内可进行该现金管理，且该 10 亿元人民币额度可循 环滚动使用；并同意公司以通知存款、协定存款等方式存放募集资金，存款期限 自公司董事会审议通过之日起不超过 12 个月。现将具体情况公告如下： | A 股代码：688428 A 股简称：诺诚健华 公告编号：2024-012 | | --- | | 港 ...

3、上表中部分合计数与各明细数直接相加之和在尾数上如有差异，是由于四舍五入所造成。 诺诚健华医药有限公司董事会 2024 年 5 月 30 日 | 姓名 | 国籍 | 职务 | 获授的限制 | 占授予权益总 | 占本激励计划预留 | | --- | --- | --- | --- | --- | --- | | | | | 性股票数量 | 数的比例 | 授予时公司已发行 | | | | | （万股） | | 股份总数的比例 | | 一、董事、高级管理人员、核心技术人员 | | | | | | | / | / | / | / | / | / | | 二、其他激励对象 | | | | | | | 董事会认为需要激励的其他员工（47 人） | | | 173.700 | 19.42% | 0.10% | | 合计 | | | 173.700 | 19.42% | 0.10% | 注：1、上述任何一名激励对象通过公司全部有效期内的股权激励计划获授的公司股票数量未超过本激 励计划提交股东大会审议时公司已发行股份总数的 1%。公司全部有效期内的股权激励计划所涉及的标的股 票总额未超过本激励计划提交股东大会审议时公司已发行 ...

欢迎各位投资者参加华安医药联合路远中举办的夏季线上策略会本场会议的主持人是华安医药团队首席谭国超老师本场是上市公司诺诚电华的一个交流很荣幸呢我们邀请到了公司领导袁总来和我们做一个今天的交流今天交流主要分为两个部分一部分呢是公司的介绍另一部分是QA的环节 首先有请公司领导袁总用20到30分钟的时间对公司的经营情况和最新的进展做一个讲解,有请袁总。好的,多谢孙老师。对,诺成建华我们专注在两个大的方向,一个是这个肿瘤,一个是自身免疫性不定。 那我们15年成立到现在接近9年的时间还是取得了一系列的进展那在这个里面呢我们因为也刚刚过去5月中我们刚刚发了我们2024年的一季度的报告给大家做一个简要的汇总首先在财务方面我们一季度营收是1.66亿人民币毛利是持续提高的达到了85.4%那研发支出1.78亿人民币 也是我们在持续在研发方面持续加强投入并且也在布局国际化方面的各个软件总体的现金结余是超过82亿人民币的为公司的快速发展还提供了非常坚实的基础然后在商业话题方面 核心产品这个已经在商业化阶段的奥布提尼我们的BTKG7收入是1.64亿人民币同比增长了9%那当然在后面的我们接下来2024年的接下来的三个季度里面我们会有一个持 ...

欢迎各位投资者参加华安医药联合路演中举办的夏季线上策略会。本场会议的主持人是华安医药团队首席谭国超老师。本场是上市公司诺诚电华的一个交流。很荣幸呢,我们邀请到了公司领导袁总来和我们做一个今天的交流。今天交流主要分为两个部分,一部分呢是公司的介绍,另一部分是QA的环节。 首先有请公司领导袁总用20到30分钟的时间对公司的经营情况和最新的进展做一个讲解,有请袁总。好的,多谢孙老师。对,诺成建华我们专注在两个大的方向,一个是这个肿瘤,一个是自身免疫性不定。 那我们一亩年成立到现在接近9年的时间还是取得了一系列的进展那在这个里面呢我们因为也刚刚过去5月中我们刚刚发了我们2024年的一季度的报告给大家做一个简要的汇总首先在财务方面我们一季度营收是1.66亿人民币毛利是持续提高的达到了85.4%那研发支出1.78亿人民币 也是我们在持续在研发方面持续加强投入并且也在布局国际化方面的各个管线总体的现金结余是超过82亿人民币的为公司的快速发展还提供了非常坚实的基础然后在商业化这方面 核心产品这个已经在商业化阶段的奥布提尼我们的BTKGT收入是1.64亿人民币同比增长了9%那当然在后面的我们接下来2024年的接下来的三个季度里 ...

Financial Performance - In the first quarter of 2024, the company achieved a total revenue of RMB 165.82 million, a decrease of 12.44% year-on-year[8] - Sales revenue from the core product, Oubatinib (Yinokai®), reached RMB 164.80 million, representing a year-on-year growth of 8.87%[8] - The gross profit margin for the first quarter of 2024 was 85.4%, an increase of 8.1 percentage points compared to 77.3% in the same period last year[7] - The company reported a net loss attributable to shareholders of RMB 142.40 million for the first quarter[8] - Total revenue for Q1 2024 was ¥165,824,020.34, a decrease of 12.43% compared to ¥189,387,628.40 in Q1 2023[20] - Net loss for Q1 2024 was ¥145,660,375.68, compared to a net loss of ¥14,229,365.40 in Q1 2023, indicating a substantial decline in profitability[20][21] - The company's basic earnings per share for Q1 2024 was -¥0.08, compared to -¥0.01 in Q1 2023, highlighting a deterioration in earnings performance[21] Research and Development - Research and development expenses totaled RMB 177.73 million, accounting for 107.18% of total revenue, an increase of 32.75 percentage points year-on-year[8] - Research and development expenses rose to ¥177,728,720.87, an increase of 26.06% from ¥140,950,687.03 in Q1 2023, reflecting a focus on innovation[20] Cash Flow and Liquidity - The company experienced a net cash outflow from operating activities of RMB 84.04 million in the first quarter[8] - Cash flow from operating activities showed a net outflow of ¥84,043,543.78, improving from a larger outflow of ¥154,802,409.78 in Q1 2023[23] - Cash and cash equivalents at the end of Q1 2024 totaled ¥4,616,481,748.24, up from ¥3,993,788,388.71 at the end of Q1 2023, indicating improved liquidity[23] - The company reported a significant increase in cash inflow from investment activities, totaling ¥502,674,850.75, compared to a net outflow of ¥1,915,385.25 in Q1 2023[23] - As of March 31, 2024, the company held cash and cash equivalents of approximately RMB 8.2 billion[7] - The company's cash and cash equivalents as of March 31, 2024, amount to ¥8,201,839,334.55, a decrease from ¥8,287,136,644.81 as of December 31, 2023[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 17,655[12] - The total number of issued shares is 1,762,582,452, with 1,497,934,235 shares (approximately 84.99%) issued in Hong Kong and 264,648,217 shares (approximately 15.01%) issued on the Shanghai Stock Exchange[12] - The top shareholder, HKSCC NOMINEES LIMITED, holds 730,634,157 shares, representing 41.44% of the total shares[14] - The second-largest shareholder, HHLR Fund, L.P. and its concerted actors, holds 208,671,222 shares, accounting for 11.84%[14] - The company has not disclosed any significant changes in shareholder relationships or concerted actions among the top shareholders[15] Assets and Liabilities - The total assets decreased to ¥9,766,283,263.59 from ¥9,919,995,852.46 in the previous quarter, reflecting a reduction in overall company size[19] - The total liabilities decreased slightly to ¥2,712,214,039.61 from ¥2,739,290,198.68, indicating a minor improvement in the company's debt position[19] - Accounts receivable decreased to ¥232,958,854.23 from ¥276,377,549.08 over the same period[18] - Total current assets decreased to ¥8,620,713,615.47 from ¥8,765,324,062.77[18] - Non-current assets totaled ¥1,145,569,648.12, down from ¥1,154,671,789.69[18] - The company reported a decrease in long-term equity investments from ¥5,660,187.95 to ¥4,320,662.46[18] Accounting and Reporting - The company has adopted new accounting standards starting from 2024, impacting the financial statements from the beginning of the year[24] - The financial report is presented by Jisong Cui, the head of the company, along with key accounting personnel[24] - The report indicates that the company is not applicable for the new accounting standards or interpretations[24] - The announcement was made by the board of directors of the company on May 13, 2024[24] - The document contains a total of 14 pages, indicating a comprehensive report[24] - The company is focused on ensuring the accuracy of financial reporting under the new standards[24] - There are no specific performance metrics or user data provided in this document[24] - Future outlook and performance guidance are not detailed in this report[24] - No information on new products, technologies, market expansion, or mergers and acquisitions is included[24] - The report does not provide any financial figures or percentage changes[24] Product Information - Oubatinib is the first and only BTK inhibitor approved for the MZL indication in China, listed as a Class I recommendation in the CSCO lymphoma treatment guidelines[7]

Financial Performance - In Q1 2024, the company achieved a total revenue of approximately CNY 165.82 million, a decrease of 12.44% year-on-year[6] - Sales revenue from the core product, Oubatinib (Yinokai®), reached CNY 164.80 million, representing a year-on-year growth of 8.87%[6] - The company reported a net loss attributable to shareholders of CNY 142.40 million for the quarter[6] - In Q1 2024, the company reported a net loss of CNY 145,660,375.68, compared to a net loss of CNY 14,229,365.40 in Q1 2023, indicating a significant decline in profitability[20] - The company recorded a total comprehensive loss of CNY -135,208,277.15 in Q1 2024, compared to a loss of CNY -100,502,461.88 in Q1 2023[21] - Basic and diluted earnings per share were both CNY -0.08, compared to CNY -0.01 in the previous year, indicating a deterioration in earnings performance[21] Research and Development - Research and development expenses totaled CNY 177.73 million, accounting for 107.18% of total revenue, an increase of 32.75 percentage points year-on-year[6] - Research and development expenses increased to CNY 177,728,720.87, compared to CNY 140,950,687.03 in Q1 2023, marking a rise of about 26%[20] Cash and Liquidity - As of March 31, 2024, the company held approximately CNY 8.2 billion in cash, ensuring sufficient liquidity for ongoing projects[5] - Cash and cash equivalents as of March 31, 2024, were ¥8,201,839,334.55, a slight decrease from ¥8,287,136,644.81 at the end of 2023[17] - Cash and cash equivalents at the end of Q1 2024 stood at CNY 4,616,481,748.24, up from CNY 3,993,788,388.71 at the end of Q1 2023, representing an increase of approximately 16%[23] - The company experienced a net cash outflow from operating activities of CNY -84,043,543.78, an improvement from CNY -154,802,409.78 in Q1 2023[22] - Investment activities generated a net cash inflow of CNY 502,674,850.75, a significant turnaround from a net outflow of CNY -1,915,385.25 in Q1 2023[22] Operating Costs - Total operating costs for Q1 2024 were ¥303,015,436.11, an increase of 45.96% from ¥207,586,324.78 in Q1 2023[19] - The company’s total operating costs were CNY 24,290,417.68, compared to CNY 42,897,028.90 in Q1 2023, showing a decrease of approximately 43%[20] Market and Product Development - The company’s three indications for Oubatinib have received coverage under the new national medical insurance directory, enhancing its market potential[4] - The company is focused on expanding its commercialization capabilities and optimizing execution strategies to accelerate growth[4] - The company has not disclosed any new product launches or technological advancements during this quarter[16] Shareholder Information - There are no significant changes in the top 10 shareholders or their shareholding percentages[15] Other Financial Metrics - The gross profit margin for Q1 2024 was 85.4%, an increase of 8.1 percentage points compared to 77.3% in the same period last year[5] - The weighted average return on equity was -2.01% for the quarter, reflecting ongoing investment in R&D and operational challenges[6] - Total assets decreased to ¥9,766,283,263.59 from ¥9,919,995,852.46 at the end of 2023[18] - Total liabilities decreased to ¥2,712,214,039.61 from ¥2,739,290,198.68 at the end of 2023[18] - Inventory as of March 31, 2024, was ¥118,157,773.43, a slight decrease from ¥119,094,840.89 at the end of 2023[17] - Long-term investments decreased to ¥4,320,662.46 from ¥5,660,187.95 at the end of 2023[17] - Non-recurring losses for the quarter amounted to CNY 8.45 million, primarily due to fair value losses on convertible loans[7] - The company reported a foreign exchange gain of CNY 2,726,913.06, contrasting with a loss of CNY -21,312,065.11 in the same quarter last year[23]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2024年4月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 諾誠健華醫藥有限公司（於開曼群島註冊成立的有限公司） 呈交日期: 2024年5月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 | 09969 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 25,000,000,000 | USD | | 0.000002 USD | | 50,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 25,000,000,000 | USD | | 0.000002 USD | | 50,000 | 本月底法定/註冊股本 ...